10.6084/m9.figshare.11709072.v1 Murat Akand Murat Akand Tim Muilwijk Tim Muilwijk Frank Van Der Aa Frank Van Der Aa Thomas Gevaert Thomas Gevaert Uros Milenkovic Uros Milenkovic Lisa Moris Lisa Moris Wim Blyweert Wim Blyweert Hendrik Van Poppel Hendrik Van Poppel Maarten Albersen Maarten Albersen Steven Joniau Steven Joniau Prognostic score predicts overall survival following complete urinary tract extirpation Taylor & Francis Group 2020 Bladder cancer radical cystectomy upper urinary tract carcinoma nephroureterectomy complete urinary tract extirpation 2020-01-24 12:59:51 Dataset https://tandf.figshare.com/articles/dataset/Prognostic_score_predicts_overall_survival_following_complete_urinary_tract_extirpation/11709072 <p><b>Purpose:</b> To evaluate the oncological outcome and complications of patients treated with complete urinary tract extirpation (CUTE) in our department, and to identify prognostic factors for survival.</p> <p><b>Methods:</b> Clinico-pathological data of patients treated with one-step or stepwise CUTE between 1999 and 2017 were collected retrospectively. Complications were classified according to the modified Clavien–Dindo classification (CDC) in the early (≤30 days) and late (>30 days) follow-up. Log-rank test was used to assess independent predictors of overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS).</p> <p><b>Results:</b> Twenty-five patients (20 male) underwent CUTE (16 one-step) for BC + unilateral/bilateral UTUC. Minor (CDC 1-2) and major (CDC3-5) complications were observed in 72% and 40% of patients, respectively, in the early postoperative period (≤30 days). Five (20%) patients died in the perioperative period (CDC 5) with a median OS of 52 days (range: 25–77). Median time to last follow-up or death was 30 months (range: 0–161). Median OS was 50 months (95% Confidence Interval [CI]: 22–118 months), while median CCS and RFS were not reached. The 5-year OS, CSS and RFS were 42.7%, 69.6% and 66.7%, respectively. A score for determining which patients would benefit from CUTE was arbitrarily developed, and showed that the patients with a score of 0–2 points (good prognosis) had a better OS than the patients with a poor prognosis (3–4 points) in the log-rank test.</p> <p><b>Conclusions:</b> Because of lower OS rates, patients with ESRD or with a CUTE score of 3–4 points are probably not ideal candidates for CUTE.</p>